EUVIMEDEUVIMED entdecken
Crossref

Development of Crohn’s Disease in a Patient with Ankylosing Spondylitis Receiving Etanercept

Emin Bodakçı

Journal of Enterocolitis · 2023

DOI: 10.14744/jenterocolitis.2023.23050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Enterocolitis, 2023. Verfasst von Emin Bodakçı.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor necrosis factor -alpha is an important cytokine that plays a role in inflammation and immune reactions.Tumor necrosis factor-alpha and its receptors are known to play a role in the pathogenesis of numerous immune-mediated diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease.It is known that anti-tumor necrosis factor agents used in inflammation suppression and remission could lead to a series of paradoxical side effects.In this paper, we presented a case with ankylosing spondylitis in whom Crohn's disease developed during etanercept treatment.A significant improvement was achieved in the symptoms and laboratory values by stopping etanercept treatment and switching to adalimumab.

Zitieren

APA

Bodakçı, E. (2023). Development of Crohn’s Disease in a Patient with Ankylosing Spondylitis Receiving Etanercept. Journal of Enterocolitis. https://doi.org/10.14744/jenterocolitis.2023.23050

Vancouver

Bodakçı E. Development of Crohn’s Disease in a Patient with Ankylosing Spondylitis Receiving Etanercept. Journal of Enterocolitis. 2023. doi:10.14744/jenterocolitis.2023.23050

BibTeX
@article{Bodak2023,
  author = {Bodakçı, Emin},
  title = {Development of Crohn’s Disease in a Patient with Ankylosing Spondylitis Receiving Etanercept},
  journal = {Journal of Enterocolitis},
  year = {2023},
  doi = {10.14744/jenterocolitis.2023.23050}
}
Kostenlos starten →